A new study has revealed a group of blood proteins that are altered in people who go on to develop multiple sclerosis (MS), in some cases more than a decade before diagnosis. The findings offer hope ...
Copyright: © 2026 The Author(s). Published by Elsevier Ltd.
A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab – a ...
Halting the insidious accumulation of irreversible disability remains the principal challenge in multiple sclerosis care. Once classified as relapsing (including relapsing-remitting and active ...
World MS Day on May 30 unites advocates to push for earlier diagnoses of multiple sclerosis, better medical training, and ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal ...
Researchers identified key differences between two widely used multiple sclerosis models, showing how each can better study myelin damage, immune responses, and repair. The findings may improve ...
The two main mouse models used to study myelin damage and repair in MS each replicate certain distinct biological features of ...
Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue.BOSTON, May 19, 2026 ...
Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue. BOSTON, May 19, 2026 ...
Transcriptomics of two prevailing models, cuprizone (CPZ) and lysophosphatidylcholine (LPC), reveal understanding of myelin loss and regeneration.
More than 1 million people across the United States live with multiple sclerosis (MS), a disease that affects the brain, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results